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The greatest risk factor for Alzheimer’s disease (AD) is age, and changes in the ageing
nervous system are likely contributors to AD pathology. Amyloid beta (Aβ) accumulation,
which occurs as a result of the amyloidogenic processing of amyloid precursor protein
(APP), is thought to initiate the pathogenesis of AD, eventually leading to neuronal
cell death. Previously, we developed an adult-onset Drosophila model of AD. Mutant
Aβ42 accumulation led to increased mortality and neuronal dysfunction in the adult
flies. Furthermore, we showed that lithium reduced Aβ42 protein, but not mRNA, and
was able to rescue Aβ42-induced toxicity. In the current study, we investigated the
mechanism/s by which lithium modulates Aβ42 protein levels and Aβ42 induced toxicity
in the fly model. We found that lithium caused a reduction in protein synthesis in
Drosophila and hence the level of Aβ42. At both the low and high doses tested, lithium
rescued the locomotory defects induced by Aβ42, but it rescued lifespan only at lower
doses, suggesting that long-term, high-dose lithium treatment may have induced toxicity.
Lithium also down-regulated translation in the fission yeast Schizosaccharomyces pombe
associated with increased chronological lifespan. Our data highlight a role for lithium and
reduced protein synthesis as potential therapeutic targets for AD pathogenesis.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of demen-
tia in the ageing population. The proportion of deaths due
to heart disease and stroke decreased by 13 and 20% respec-
tively between 2000 and 2008, while those due to AD increased
by a staggering 66% (Alzheimer’s Association, 2012). AD is
a neurodegenerative disorder characterized by the presence
of amyloid beta (Aβ) deposits and neurofibrillary, hyper-
phosphorylated tau tangles in the brain (Spires and Hyman,
2005). Age is the major risk factor for AD, and the fruit fly
Drosophila has been used to demonstrate experimentally that
the neurons of older adult flies are intrinsically more suscep-
tible to Aβ toxicity (Rogers et al., 2012). The ageing process
could contribute to increased vulnerability to protein toxic-
ity through several routes, including reduced protein turnover
through inefficient proteasome- and autophagy-mediated clear-
ance mechanisms (Rubinsztein et al., 2011; Rogers et al., 2012).
Interestingly, Aβ accumulation has been linked to several pro-
cesses affected by ageing. For instance, in a Drosophila model
of AD, Aβ increased the appearance of abnormal autophagic
vesicles, which lost their structural integrity and function
with age, and thus influenced neuronal integrity (Ling et al.,
2009).
In a previous study, we developed an adult-onset Drosophila
model of AD, using an inducible gene expression system to
express Arctic mutant Aβ42 specifically in adult neurons (Sofola
et al., 2010). Aβ42 accumulated in these flies and they dis-
played increased mortality together with progressive neuronal
dysfunction. We also demonstrated that, if we treated the adult
flies expressing Aβ chronically with lithium, we rescued toxicity
caused by Aβ. Furthermore, we found that Aβ protein, but not
mRNA levels were reduced upon lithium treatment (Sofola et al.,
2010).
Lithium has been used to treat psychiatric conditions such
as bipolar disorder, and it also has interesting neuroprotective
effects (Rybakowski, 2011). Lithium is able to promote neuro-
genesis, and increase the levels of neurotrophins such as brain-
derived neurotrophic factor (BDNF), and to inhibit glycogen
synthase kinase-3 (GSK-3), which is involved in AD (Machado-
Vieira et al., 2009; Rybakowski, 2011). Lithium also reduces
amyloid production by affecting APP processing/cleavage in
cells and mice, presumably by down regulating the levels of
phosphorylated APP (Phiel et al., 2003; Rockenstein et al., 2007).
Lithium can also influence various ageing-regulated pro-
cesses that could interfere with protein turnover and conse-
quently affect neurological function. For instance, lithium has
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been shown to induce autophagy (Sarkar et al., 2005), pro-
mote proteasome-mediated degradation (Jing et al., 2013), and
influence components of the translational machinery (Bosetti
et al., 2002; Karyo et al., 2010). Also, inhibiting GSK-3 in
HCC1806 cells by a GSK-3 inhibitor or knockdown of GSK-3β
has been reported to significantly decrease polysome assem-
bly, and thus affect translation (Shin et al., 2014). GSK-3 was
shown in these cells to partially exert its effects on transla-
tion via eIF4E-binding protein 1 (4E-BP1). Knocking down
4E-BP1 only partially restored the cap-dependent translation
suppressed by GSK-3 inhibition, suggesting that GSK-3βmay reg-
ulate other components involved in protein synthesis (Shin et al.,
2014).
In this study, we investigated underlying mechanism/s by
which lithium can reduce Aβ protein levels and thus pathol-
ogy in the adult-onset, Drosophila model of AD. Aβ peptide
is directly expressed in this model, and therefore, any effect of
lithium on Aβ levels is not due to its ability to alter APP process-
ing, but rather a consequence of its role in protein synthesis or
degradation.
MATERIALS AND METHODS
FLY STOCKS AND MAINTENANCE
All fly stocks were maintained at 25◦C on a 12:12-h light:dark
cycle at constant humidity on a standard sugar-yeast (SY)
medium (15 gl−1 agar, 50 gl−1 sugar, 100 gl−1 autolyzed yeast,
100 gl−1 nipagin and 3ml l−1 propionic acid). Adult-onset,
neuronal-specific expression of Arctic mutant Aβ42 peptide was
achieved by using the elav GeneSwitch (elavGS)-UAS system
[GAL4-dependent upstream activator sequence; (Osterwalder
et al., 2001)]. ElavGS was derived from the original elavGS
301.2 line (Osterwalder et al., 2001) and obtained as a
generous gift from Dr H. Tricoire (CNRS, France). UAS-
ArcAβ42 were obtained from Crowther et al. (2005). elavGS
and UAS-lines used in all experiments were backcrossed six
times into the w1118 genetic background. For the fly AD
model, flies carrying homozygous UAS-ArcAβ42;elavGS con-
structs were out-crossed to either w1118 flies, or flies express-
ing EGFP in a w1118 background; and adult-onset neuronal
expression was induced in the female progeny by treatment
with mifepristone (RU486; 200μM) added to the standard SY
medium.
LITHIUM TREATMENT PROTOCOL
Lithium chloride solution was made at 10M concentration
and added to 200μM RU486 standard SY medium for final
concentrations of lithium.
LIFESPAN ANALYSES
For all experiments, flies were raised at a standard density on
standard SY medium in 200mL bottles. Two days after eclosion
once-mated females were transferred to experimental vials con-
taining SY medium with or without RU486 (200μM) at a density
of 15 flies per vial. Deaths were scored almost every other day and
flies were transferred to fresh food. Data are presented as survival
curves and statistical analysis was performed using log-rank tests
to compare survival of groups.
NEGATIVE GEOTAXIS ASSAYS
Climbing assays were performed at 25◦C according to previously
published methods (Sofola et al., 2010). Climbing was analyzed
every 2–3 days post-RU486 treatment. Fifteen adult flies were
placed in a vertical column (25 cm long, 1.5 cm diameter) with
a conic bottom end, tapped to the bottom of the column, then
their climb to the top of the column was analyzed. Flies reach-
ing the top and flies remaining at the bottom of the column after
a 45 s period were counted separately, and three trials were per-
formed at 1min intervals for each experiment. Scores recorded
were the mean number of flies at the top (ntop), the mean num-
ber of flies at the bottom (nbottom) and the total number of flies
assessed (ntot). A performance index (PI) defined as ½(ntot + ntop
- nbottom)/ ntot) was calculated. Data are presented as the mean
PI ± s.e.m. obtained in three independent experiments for each
group, and analyses of variances (ANOVA) were performed using
JMP 10.0 software.
QUANTIFICATION OF Aβ42 PEPTIDE
To extract total Aβ42, five Drosophila heads were homoge-
nized in 50μl GnHCl extraction buffer (5M Guanidine HCl,
50mM Hepes pH 7.3, protease inhibitor cocktail (Sigma, P8340)
and 5mM EDTA), centrifuged at 21,000 g for 5min at 4◦C,
and cleared supernatant retained as the total fly Aβ42 sample.
Aβ42 content was measured in Arctic mutant Aβ42 flies and
controls using the hAmyloid β42 ELISA kit (HS) (Millipore).
Samples were diluted in sample/standard dilution buffer and
the ELISA performed according to the manufacturers’ instruc-
tions. Protein extracts were quantified using the Bradford pro-
tein assay (Bio-Rad protein assay reagent; Bio-Rad laboratories
(UK) Ltd) and the amount of Aβ42 in each sample expressed
as a ratio of the total protein content (pmol/g total pro-
tein). Data are expressed as the mean ± s.e.m. obtained in
three independent experiments for each genotype. ANOVAs and
Tukey’s-HSD post-hoc analyses were performed using JMP 7.0
software.
WESTERN BLOTTING
The same number of Drosophila heads for each sample
were homogenized in Laemmli sample buffer containing β-
mercaptoethanol and boiled for 10min. Proteins were separated
on SDS polyacrylamide gels and blotted onto nitrocellulose
membranes. Membranes were incubated in a blocking solution
containing 5% milk proteins in TBST for 1 hr at room temper-
ature, then probed with primary antibodies diluted in TBST +
5% BSA overnight at 4◦C. Antibodies were from Cell Signaling
unless specified. GFP antibody was used at 1 in 1000 dilution
(2955), phospho eIF2B and total eIF2B at 1 in 1000 (Ab4775 and
Ab32713), phospho and total eEF2 at 1 in 500 (2331 and 2332),
and phospho S6K (9206), total S6K at 1 in 1000 [made from pre-
viously published sequence (Pearson et al., 1995)]. Appropriate
secondary antibodies were used at a dilution of 1 in 10,000.
PROTEASOME ACTIVITY
Fly heads were homogenized in 25mM Tris, pH 7.5 and
protein content determined by Bradford assay. Chymotrypsin-
like peptidase activity of the proteasome was assayed the
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using fluorogenic peptide substrate Succinyl-Leu-Leu-Val-Tyr-
amidomethylcoumarin (LLVY-AMC), based on a previously pub-
lished protocol (Bulteau et al., 2002; Rogers et al., 2012). 20μg of
crude fly head homogenate total protein was incubated at 37◦C
with 25μM LLVY-AMC in a final volume of 200μLs. Enzymatic
kinetics were measured in a temperature-controlled microplate
fluorimeter (Tecan Infinite M200), at excitation/emission wave-
lengths of 360/460 nm, measuring fluorescence every 2min
for 1 h. Proteasome activity was determined as the slope
of AMC accumulation over time permg of total protein
(pmoles/min/mg).
35S-METHIONINE INCORPORATION
Protein translation was measured in fly heads using a method
adapted from Bjedov et al. (2010). Standard SY medium was
first supplemented with 100μCi 35S methionine/mL of food
(American Radiolabeled Chemicals 1mCi/37MBq ARS0104A). 15
flies were transferred to each vial containing 1mL radioactive SY
medium. After three-hours of feeding, flies were transferred to
non-radioactive SY for 30min in order to purge any undigested
radioactive food from the intestines. Flies that were in contact
with the radioactive food for 1min were used as a background
control. Flies were then decapitated using liquid nitrogen and the
heads and bodies homogenized in 1% SDS and heated for 5min
at 95◦C. Samples were centrifuged twice for 5min at 16,000 g.
Proteins were precipitated by the addition of the same volume
of 20% cold TCA (10% TCA final concentration) and incubated
for 15min on ice. Samples were then centrifuged at 16,000 g for
15min, the pellet washed twice with acetone and re-suspended in
200μl of 4M guanidine-HCl.
Samples (100μl) were mixed with 3mL of Fluoran-Safe 2,
BDH and radioactivity counted in a liquid scintillation analyzer
(TriCarb 2800TR, Perkin Elmer), with appropriate quench cor-
rections. SDS-homogenates, prior to TCA precipitation, were also
sampled and analyzed as a measure of the total radioactivity
(incorporated and un-incorporated) present. Total protein for
each sample was determined by Bradford assay and a translation
index was calculated as follows: (TCA protein cpm/total cpm)/μg
protein per sample.
CHRONOLOGICAL LIFESPAN ASSAYS IN FISSION YEAST
Standard S. pombe laboratory strain 972 h− cells were grown in
EMM2 as previously described (Rallis et al., 2013). When cultures
reached a stable maximal density, cells were harvested, serially
diluted and plated on YES plates. The measurement of Colony
Forming Units (CFUs) was taken as time-point 0 at the beginning
of CLS curve (i.e., 100% cell survival). Measurements of CFUs
were conducted on the following days. Error bars represent stan-
dard deviation calculated from three independent cultures, with
each culture measured three times at each time-point. Statistical
significance (t-test) was determined at the time-point when
medial lifespan (50% cells dead) was reached for the untreated
cells.
POLYSOME PROFILING IN FISSION YEAST
Translational profiles were acquired as previously described
(Rallis et al., 2013). Briefly, S. pombe cells were treated with
100μM Cycloheximide for 5min. Cells were then collected by
centrifugation at 3500 rpm for 5min and diluted in 20mM
Tris-HCl pH 7.5, 50mM KCL, 10mM MgCl supplemented
with protease (PMSF), 100μM cycloheximide, 1mM DTT and
200 ng/mL Heparin. Cells were lysed in a Fastprep-24 machine
using glass beads. Sucrose gradients (10–50%) were generated
using a Biocomp Gradient Master, and protein preparations were
loaded and centrifuged at 35,000 rpm for 2 h 40min. Polysome
gradients were then loaded to the fractionator to obtain the
translational profiles.
POLYSOME PROFILING IN DROSOPHILA
Polysome profiles were generated as previously described with
minor modifications (Dinkova et al., 2005). Heads (300) were
homogenized on ice in 1200μl polysome extraction buffer
(300mMNaCl, 50mM Tris-HCL (pH 8.0), 10mMMgCl2, 1mM
EGTA, 200mg heparin/ml, 400 U RNAsin/ml, 1.0mM phenyl-
methylsulfonyl fluoride, 0.2mg cycloheximide/ml, 1% Triton X-
100, 0.1% Sodium Deoxycholate). Lysates were mixed gently and
placed on ice for 10min. Debris was the removed by spinning
at 20,000 g (4◦C) for 10min and the supernatant was layered
onto a 10–50% sucrose gradient in high salt resolving buffer
(140mM NaCl, 25mM Tris-HCL (pH 8.0), 10mM MgCl2).
Using a Beckman SW41Ti rotor (38,000 rpm at 90min, 4◦C)
polysomes and ribosomal subunits were separated before the gra-
dients were fractionated. Profiles were continuously monitored
(Ab 252 nm) using a Teledyne density gradient fractionator.
STATISTICAL ANALYSES
Data are presented as means ± s.e.m. obtained in at least three
independent experiments. JMP (version 10.0) software (SAS
Institute, Cary, NC, USA) was used for data analyses.
RESULTS
LITHIUM REDUCED Aβ LOAD IN ARCTIC Aβ42 EXPRESSING FLIES
THROUGH PROTEIN CLEARANCE/DEGRADATION-INDEPENDENT
MECHANISMS
To understand the mechanism/s by which lithium reduces Aβ42
protein level, we first investigated the speed of Aβ42 accumula-
tion after induction of expression, in the presence and absence
of lithium. We measured total Aβ protein in the flies express-
ing Arctic mutant Aβ42 specifically in adult neurons (elav gene
switch system was used to induce Aβ expression with the acti-
vator mifepistrone, RU486/RU) (Sofola et al., 2010) at a very
early time-point, 2 days post Aβ induction. We found by ELISA
analysis that even at this early time point, UAS-ArcAβ42/UAS-
gfp;elavGS/+ +RU +Li flies that were fed either 25 or 100mM
lithium showed a major reduction in total Aβ burden in compari-
son to UAS-ArcAβ42/UAS-gfp;elavGS/+ +RU controls, P < 0.01
and P < 0.001 respectively (Figure 1A). These data suggest that
lithium may affect synthesis rather than degradation of Aβ,
because a reduction in Aβ levels was already present at such an
early time point.
Next, we directly assessed the effects of lithium on degradation
of Aβ42. We induced Aβ expression for 6 days in the presence
of lithium (UAS-ArcAβ42/UAS-gfp;elavGS/+ +RU +Li), then
stopped Aβ induction and divided the flies randomly into two
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FIGURE 1 | Lithium reduced the level of Aβ42 peptide in the adult
Drosophila nervous system. (A) Lithium reduced amyloid levels of Arctic
Aβ42 flies at a very early time-point. Protein levels of UAS-ArcAβ42/
UAS-gfp;elavGS/+ flies on +RU486 SY medium, and UAS-ArcAβ42/
UAS-gfp;elavGS/+ flies on +RU +lithium (LiCl), were measured by ELISA
at 2 days post-induction (see Materials and Methods). Data were compared
using One-Way ANOVA, number of independent tests (n) = 4. ∗P < 0.01
and ∗P < 0.001 when comparing UAS-ArcAβ42/UAS-gfp;elavGS/+ +RU to
UAS-ArcAβ42/UAS-gfp;elavGS/+ +RU +LiCl 25 or 100mM respectively.
(B) Protein levels of UAS-ArcAβ42/UAS-gfp;elavGS/+ flies on RU +
100mM LiCl medium at 6 days post induction, and then switched to –RU
LiCl for 5 days were not significantly different from ArcAβ42/UAS-gfp;
elavGS/+ flies on RU + 100mM LiCl medium for 6 days, P = 0.6, nor
were UAS-ArcAβ42/UAS-gfp;elavGS/+ flies on +RU 6 days post induction
different in comparison to UAS-ArcAβ42/UAS-gfp;elavGS/+ flies on +RU
–LiCl for 6 days switched on to –RU + LiCl for 5 days, P = 0.7. Data were
compared using One-Way ANOVA, number of independent tests (n) = 4.
(C) Proteasome activity, as measured using the fluorogenic peptide
substrate LLVY-AMC, was not changed in flies over-expressing Arctic Aβ42
with or without LiCl treatment. Data are presented as mean activities
(pmol/min/mg protein) ± s.e.m., P = 0.72 and 0.82 for 10 and 100mM Li
(n = 5).
groups, in one of which lithium treatment was continued for a
further 5 days (UAS-ArcAβ42/UAS-gfp;elavGS/+ -RU+Li), while
no lithium was added to the food of the control group (UAS-
ArcAβ42/UAS-gfp;elavGS/+ -RU -Li). Thus, if lithium promoted
degradation of Aβ, then the level of Aβ at the end of the treatment
period should have been lower in the flies with continued lithium
treatment. Aβ levels at the end of the 11-day period did not differ
significantly between the two groups (Figure 1B), indicating that
lithium treatment did not enhance degradation of Aβ. To confirm
this finding, we again induced Aβ expression for 6 days, but in
the absence of lithium (UAS-ArcAβ42/UAS-gfp;elavGS/+ +RU -
Li), then stopped Aβ induction and divided the flies randomly
into two groups, one of which was frozen immediately, while
in the other, lithium treatment was administered for 5 days
(UAS-ArcAβ42/UAS-gfp;elavGS/+ -RU+Li). Aβ levels at the end
of the 5-day lithium treatment period did not differ significantly
from levels in the untreated, 6-day old flies (Figure 1B). These
data suggest that lithium does not promote Aβ degradation or
clearance, and point instead to a role in Aβ protein synthesis.
We also tested if lithium modulated proteasome activity in Aβ
expressing flies (2 days post Aβ induction) and found that at
10 and 100mM doses it did not (Figure 1C), consistent with
our finding that lithium does not appear to affect Aβ protein
degradation.
LITHIUM DOWN-REGULATED TRANSLATION
To determine whether the effect of lithium on Aβ protein
level was specific to Aβ, we investigated whether it affected
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the level of green fluorescent protein (GFP), a protein that
is irrelevant to AD pathology. Surprisingly, we found that
100mM lithium significantly reduced levels of GFP in the
neurons of adult flies (UAS-egfp/+;elavGS/+ +RU), P = 0.01
(Figure 2A). These data suggest that lithium affects protein syn-
thesis through a mechanism that is not specific to Aβ. To
determine whether overall level of translation was reduced by
lithium, we carried out S-methionine radioactive tracer exper-
iments in UAS-egfp/+;elavGS/+ flies. Interestingly, we found
lower 35S-methionine incorporation into protein in the bodies
of flies treated with lithium (pooled data of 10 and 100mM
lithium) in comparison to untreated control flies (Figure 2B),
P < 0.05. Based on this finding, we measured the effect of
lithium on polysome profiles of Aβ flies, as an indication
of activity of the translation machinery. There was a signif-
icant reduction in the ratio of high (polysomes >4) to low
(monosome/polysome 1-2-3) fraction in flies treated with lithium
(10mM) (UAS-ArcAβ42/+;elavGS/+ +RU +Li) in comparison
to untreated controls (UAS-ArcAβ42/+;elavGS/+ +RU flies),
0.34 vs. 0.40, P < 0.001 (Figure 2C), again demonstrating that
lithium reduced activity of the translation machinery, possibly
through a stall in translation initiation.
We next determined whether lithium exerted its effect on
translation through an effect on the activity of the mechanis-
tic target of rapamyicin (mTOR) pathway, which is involved
in control of translation. S6K is a phosphorylation tar-
get of mTOR kinase in the mTORC1 complex (Bjedov and
Partridge, 2011); interestingly, both phosphorylated S6K and
total S6K were reduced in Aβ flies treated with lithium (UAS-
ArcAβ42/+;elavGS/+ +RU +Li) in comparison to untreated
flies (UAS-ArcAβ42/+;elavGS/+ +RU) (Figure 3A). However,
the ratio of phosphorylated S6K to total S6K was not significantly
FIGURE 2 | Lithium reduced overall protein synthesis/translation. (A)
Protein levels of UAS-egfp/+;elavGS/+ flies on +RU486 SY medium, and
UAS-egfp/+;elavGS/+ flies on +RU +100mM LiCl were measured by
Western blot analyses at 7 days post-induction (see Materials and Methods).
GFP levels were significantly reduced when comparing UAS-egfp/+;elavGS/+
+RU to UAS-egfp/+;elavGS/+ +RU +LiCl 100mM, ∗P < 0.001. Data were
compared using One-Way ANOVA, number of independent tests (n) = 6. (B)
Protein synthesis was reduced in pooled UAS-egfp/+;elavGS/+ +RU +LiCl
10mM and Li 100mM treated flies in comparison to UAS-egfp/+;elavGS/+
+RU flies measured by 35S-methionine incorporation, ∗P < 0.05. Data were
analyzed by One-Way ANOVA (n = 7 for +RU and n = 13 for +RU +LiCl
treated flies). (C) Polysome profiles showed a reduction in translation in
lithium treated Aβ expressing flies, measured by calculating the area under
the different fractions, and their ratios (area under the first 3 peaks for low
fraction, and >4 for high, ratio >4/1-2-3) P < 0.001. Data were analyzed by
paired t-test (n = 5). One representative figure is shown.
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 190 | 5
Sofola-Adesakin et al. Lithium suppresses Aßpathology by inhibiting translation
FIGURE 3 | (A) Lithium reduced protein levels of phosphorylated and total
S6K. There was no change in the ratio of phosphorylated S6K to total S6K
protein levels when UAS-ArcAβ42/+;elavGS/+ +RU +LiCl 100mM flies are
compared to UAS-ArcAβ42/+;elavGS/+ +RU controls, P = 0.2 (n = 3) (B)
Rapamycin did not reduce Aβ levels in UAS-ArcAβ42/+;elavGS/+ +RU
+50μM flies in comparison to UAS-ArcAβ42/+;elavGS/+ +RU untreated
flies, P = 0.8 (n = 3).
different between the two groups (Figure 3A). In these blots,
because of the possibility that total protein content of the flies
could have been altered by lithium, samples derived from a
fixed number of fly heads were used. Interestingly, actin levels
did not seem to be affected by lithium and were used as an
additional loading control. This finding suggests that either the
turnover rate of actin is very low, or there is a subset of proteins
that is not down-regulated by lithium. Treatment of Aβ express-
ing flies (UAS-ArcAβ42/+;elavGS/+ +RU) with rapamycin, an
inhibitor of mTOR that inhibits translation and extends lifespan
in Drosophila (Bjedov et al., 2010) also did not reduce the levels
of Aβ in the Aβ-expressing flies (Figure 3B), and nor did it ame-
liorate the Aβ-induced toxicity (Supplemental Figure 1A). These
data suggest that lithium did not act through the mTOR path-
way to reduce translation in the Aβ-expressing flies, and that the
reduced levels of total and phosphorylated S6K were instead a
consequence of a general reduction in translation.
Lithium has been shown to regulate the translation initiation
factor eIF2B in rats (Bosetti et al., 2002) and the elongation factor,
eEF-2 in SH-SY5Y cells and mice (Karyo et al., 2010). We inves-
tigated whether lithium reduced protein synthesis by regulating
one or both of these factors. Again, we observed a reduction in
both the phosphorylated and total forms of eIF2B-epsilon and
eEF-2 in Aβ expressing flies treated with 100mM lithium (UAS-
ArcAβ42/+;elavGS/+ +RU+Li) in comparison to untreated flies
(UAS-ArcAβ42/+;elavGS/+ +RU), but the ratio of phosphory-
lated to total eIF2B-epsilon or eEF-2 was not significantly affected
(Figures 4A,B). These data again demonstrate that lithium down-
regulated protein levels, but they do not point to a specific role for
eIF2B-epsilon or eEF-2.
Indeed, a clear-cut explanation of the effects of lithium may
be elusive, since translation of many proteins involved in the
protein synthesis machinery is presumably inhibited by lithium.
Furthermore, we used a high dose of lithium (100mM) to max-
imize our chances of identifying these downstream factors that
are responsible for the effect of lithium on translation, and were
unable to identify a specific role for the proteins we tested; and
thus did not test lower concentrations of lithium. Overall, the
data suggest that the reduction in Aβ levels we observe upon
lithium treatment is as a consequence of reduction in protein
synthesis, probably because of reduced expression of multiple
proteins involved in initiation of translation, but do not identify
the specific targets responsible.
LITHIUM ALSO INHIBITS PROTEIN SYNTHESIS IN FISSION YEAST
Reduction in protein synthesis has been frequently linked to
increased lifespan, possibly attributable to both a reduction in
energy consumption, because translation requires a significant
amount of the energy budget, and a reduction in mis-translated
polypeptides (Browne and Proud, 2002; Proud, 2002; Hansen
et al., 2007; Hipkiss, 2007). Additionally, lithium has been shown
to cause significant lifespan-extension in the nematode worm
C. elegans and in Drosophila (McColl et al., 2008; Kasuya et al.,
2009; Zarse et al., 2011). Therefore, we decided to turn into
a simpler system to determine whether lithium has an evolu-
tionarily conserved effect on translation, and whether it has an
associated effect on lifespan. Unicellular yeasts have been piv-
otal in the advancement of understanding of mechanisms of
ageing (Kaeberlein et al., 2005; Rallis et al., 2013). Fast-growing
fission yeast cells in mid-log phase were treated with 0.1mM
lithium chloride for 1 h and their translational profiles were com-
pared to those of untreated (control) cells. Following lithium
treatment, translation was reduced: high (polysomes >4) to low
(monosome/polysome 1-2-3) ratios were lower (0.51) in lithium
treated yeast cells in comparison to control cells (0.63), P < 0.001
(Figure 5A). Interestingly, the same dose of lithium extended the
chronological lifespan of fission yeast, P = 0.001 (Figure 5B).
Yeast is hence an ideal model organism in which to perform
a genetic screen to identify the relevant targets of lithium for
reduced protein synthesis and increased lifespan.
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FIGURE 4 | (A,B) Lithium reduced protein levels of phosphorylated and
total eIF2Be and eEF-2. There was no change in the ratio of
phosphorylated eIF2Be or eEF-2 to total protein levels of eIF2Be or eEF-2
in UAS-ArcAβ42/+;elavGS/+ +RU +LiCl 100mM flies in comparison to
UAS-ArcAβ42/+;elavGS/+ +RU controls, P = 0.6 and 0.7 respectively
(n = 3).
LITHIUM EXTENDED LIFESPAN OF FLIES EXPRESSING Aβ
Since we observed an association between reduced global protein
synthesis and increased longevity in fission yeast, we determined
whether lithium could also extend the survival of Aβ express-
ing flies. We measured lifespan of flies expressing Arctic Aβ42
(UAS-ArcAβ42/+;elavGS/+ +RU) and treated chronically with
different concentrations of lithium from two days post-eclosion.
Flies expressing Arctic Aβ42 in adult neurons had a shortened
median and maximum lifespan as previously reported (Sofola
et al., 2010), which could be extended with 10, 25, and 50mM
(P < 0.001 for all doses), but not with 1 or 100mM lithium
(Figure 5C). The data suggest that above a certain a thresh-
old, somewhere between 50 and 100mM, lithium no longer
rescued the shortened lifespan of flies expressing Aβ, possi-
bly because it became toxic. However, this toxicity with a high
lithium dose was only evident when taken long term and/or
in older flies, since both 10mM (Supplemental Figure 1B) and
100mM lithium previously published (Sofola et al., 2010)
were able to protect against the Aβ-induced locomotor dys-
function measured after shorter term treatment and earlier
in life.
DISCUSSION
Human life expectancy continues to increase at a steady rate
in most countries worldwide, and has done so by almost 3
months per year in the last 160 years (Oeppen and Vaupel, 2002).
Therefore, it is of great importance to tackle ageing-related dis-
eases such as AD, because they are becoming increasingly preva-
lent. Because age is the biggest risk factor for AD, interventions
that promote general increases in health during ageing could also
be important and beneficial in AD.
Lithium is becoming increasingly implicated as a drug that can
ameliorate ageing and neurodegenerative diseases. Several groups
have shown that it extends lifespan in model organisms such as
the nematode worm C. elegans and Drosophila (McColl et al.,
2008; Kasuya et al., 2009; Zarse et al., 2011). Here, we showed that
it also extends lifespan in fission yeast Schizosaccharomyces pombe,
highlighting that this effect is conserved over large evolutionary
distances. Fission yeast is an ideal organism for genetic screens,
and future work should identify the molecular targets of lithium
both for control of protein synthesis and of lifespan. Furthermore,
slightly higher levels of lithium present in the drinking water have
been reported as associated with reduced mortality in a Japanese
human population (Zarse et al., 2011).
A substantial body of work has demonstrated that several
neurodegenerative diseases and neurological disorders, including
but not confined to stroke, schizophrenia, Fragile X syndrome,
Huntington’s disease and Parkinson’s disease, benefit from the
therapeutic properties of lithium (Chiu et al., 2011). In addition,
several studies have investigated whether lithium has a beneficial
effect in AD pathogenesis. Clinical trials conducted with lithium
have yielded conflicting results; some have found benefits, whilst
others have not (Nunes et al., 2007; Macdonald and Briggs, 2008;
Hampel et al., 2009). Interestingly, a correlative study conducted
in patients with bipolar disorder, suggested that patients that had
been on chronic lithium treatment showed a reduced incidence
of AD in comparison to patients that had not been on treatment
(Nunes et al., 2007). And amore recent small-scale clinical trial on
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FIGURE 5 | Lithium reduced overall protein synthesis/translation and
extended lifespan in fission yeast. (A) Polysome profiles showed a
reduction in translation in lithium treated fission yeast cells. The area under
the different fractions and their ratios were calculated (area under the first 3
peaks for low fraction, and >4 for high, fraction, ratio >4/1-2-3). Data were
analyzed by paired t-test (n = 3), P < 0.001. (B) 0.1mM LiCl increased the
chronological median lifespan of fission yeast (paired t-test comparing
triplicates of lifespan values at 50% survival/medial lifespan, P = 0.001). (C)
Survival curves of flies expressing Arctic Aβ42 with or without lithium
treatment are depicted, data were compared using the log-rank test,
comparing UAS-ArcAβ42/+;elavGS/+ +RU +LiCl 1, 10, 25, 50 or 100mM
flies to UAS-ArcAβ42/+;elavGS/+ +RU controls. No significant difference
was seen between UAS-ArcAβ42/+;elavGS/+ +RU controls and
UAS-ArcAβ42/+;elavGS/+ +RU +LiCl 1 or 100mM, P = 0.24 and 0.17
respectively, a significant difference was observed with 10, 25, and 50mM
LiCl, P < 0.001.
mild cognitive impaired (MCI) patients found that low doses of
lithium slowed cognitive decline (Forlenza et al., 2011). The inves-
tigators suggested that a reason for the previous conflicting data
on the efficacy of lithium was probably attributable to the patho-
logical states/stages at which the patients were given lithium. It is
becoming increasingly evident that drug trials are most likely to
yield positive effects when initiated early, at the MCI stage.
Our results add to existing data suggesting that lithium could
be beneficial in ameliorating Aβ toxicity, and should be consid-
ered for a potential large-scale trial on MCI patients. It has the
added advantage of being an already approved drug, used to treat
bipolar patients. It does have side-effects, but these are mini-
mal at the low doses used in the recent small-scale clinical study
(Forlenza et al., 2011). We also found that there are limits to
the beneficial/therapeutic benefits of lithium in fission yeast in
chronological lifespan—lithium was unable to increase chrono-
logical lifespan at higher doses (data not shown) as well as in
the Drosophila AD model. Previously, we showed in Sofola et al.
(2010) that administering both 30 and 100mM lithium into the
fly food are effective in modulating Aβ neuronal toxicity as evi-
denced by the improved locomotor function in young flies (Sofola
et al., 2010). These lithium concentrations were initially chosen
based on the paper by Dokucu et al. (2005)—they showed that
lithium concentrations ranging from 10 to 100mM lithium in
the fly food translates to roughly 0.05–0.4mM in the fly tissue
(Dokucu et al., 2005), so well below the toxic levels in patients
and mice (Wood et al., 1986; Schou, 2001; Can et al., 2011). In
this paper, we show that both 25 and 100mM lithium reduce Aβ
levels in a dose dependent manner at an early time point. We also
find that lower doses of Lithium (10 and 25mM) rescue the short-
ened longevity of the Aβ flies, but 100mM lithium was unable
to extend lifespan when given to the flies throughout adulthood.
It will be important to determine the therapeutic thresholds for
lithium in patients that could offer therapeutic benefits without
overt side effects.
Similar to the published data on the role of GSK-3 inhibi-
tion in down-regulating translation in HCC1806 cells (Shin et al.,
2014), we find that lithium is able to reduce translation in fis-
sion yeast and flies, suggesting that perhaps some of the effect of
lithium on translation down-regulation is via GSK-3 inhibition.
However, this is correlative and future work will involve carry-
ing out epistasis interactions between lithium and GSK-3, and
identifying molecular targets of GSK-3 and lithium for control
of protein synthesis.
Nonetheless, our study highlights the potential benefits of
lithium through down-regulation of translation, associated with
extension of lifespan in very distantly related organisms. By
reducing protein synthesis, lithium may reduce the increased
proteostatic burden in ageing, a recognized hallmark of ageing
(López-Otín et al., 2013). Lithium is also of specific benefit in
AD, because of its ability to down-regulate translation, and hence
levels of proteins involved in promoting the presence of toxic Aβ.
The mutant Arctic Aβ42 protein present in the transgenic flies
used in this study has a propensity to aggregate faster than wild
type Aβ (Spires and Hyman, 2005). However, we have observed
both soluble and insoluble Aβ in the Arctic Aβ42 flies [(Rogers
et al., 2012), and data not shown]; and the ability of lithium to
reduce translation of the Aβ peptide without affecting its clear-
ance may lower the level of soluble Aβ. In a wider context, lithium
might be beneficial in ameliorating toxicity of AD by lowering
expression of APP and of proteins that are involved in the genera-
tion of Aβ from APP. Our model does not express full length APP,
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and may therefore not include other potential/additional bene-
fits of lithium on Aβ toxicity. As well as the increased ratio of
Aβ42 to Aβ40 peptide observed in familial AD cases with APP
mutations (De Jonghe et al., 2001), increased levels of APP could
also contribute to AD pathogenesis. Indeed, patients with Down
syndrome have a high risk of developing AD possibly due to tri-
somy of the APP gene which leads to increased APP expression
(Wiseman et al., 2009). Also, several mutations in the APP pro-
moter region were found to significantly increase APP expression
in SH-SY5Y cells, and were associated with risk for AD (Theuns
et al., 2006).
The ability of lithium to down-regulate translation could
therefore be beneficial at several stages in AD pathogenesis.
Lithium might also have therapeutic benefits for other neu-
rodegenerative disorders that are caused by over-expression of
wild type or mutant forms of proteins such as α-synuclein in
Parkinson’s disease. Lithium could also reduce the production
of mis-translated polypeptides, and free proteases or/and chap-
erones that can then participate in cellular proteostasis (Proud,
2002; Singleton et al., 2003). Furthermore, diseases where protein
turnover is compromised by loss of function of the degrada-
tion machinery could also benefit from lowering the burden of
protein production hence reducing cellular stress. This could be
particularly important in lysosomal storage diseases, where the
intrinsic function of the degradative machinery is compromised
(Kinghorn, 2011; Sarkar et al., 2013). Moreover, induction of
autophagy in some cases increases the load of an already dysfunc-
tional lysosome, worsening the cellular proteostatic stress (Wong
and Cuervo, 2010; Nixon and Yang, 2011). Hence lowering the
production of proteins could again be a viable mechanism to
restore proteostasis. Other neurodegenerative models where the
role of lithium in lowering protein translation could be ben-
eficial are, for example, the Drosophila models of Pink1 and
Parkin, which do not include the over-expression of toxic proteins
(Whitworth et al., 2006; Castillo-Quan, 2011). Flies lacking either
of these proteins accumulate unfolded proteins in mitochondria,
resulting in mitochondria impairment (Pimenta de Castro et al.,
2012). It would be interesting to study whether lithium could
ameliorate mitochondrial stress by reducing the production of the
proteins accumulating in the mitochondria of the Pink1 or parkin
null flies. Lithium could hence be a useful drug with an overall
benefit for health during ageing and protection against AD and
other neurodegenerative diseases.
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fnagi.
2014.00190/abstract
Supplemental Figure 1 | (A) Rapamycin did not rescue the climbing
phenotype of UAS-ArcAβ42/+;elavGS/+ flies on +RU486 +200μM
rapamycin, P = 0.83 (B) Lithium suppressed the locomotor dysfunction
phenotype, P < 0.05. Climbing ability of UAS-ArcAβ42/UAS-gfp;elavGS/
+ +RU486 and UAS-ArcAβ42/+;elavGS/+ flies on +RU486 +LiCl 10mM
SY medium or +Rapamycin 200μM was assessed at the indicated
time-points (see Materials and Methods). Data are presented as the
percentage climbing performance of flies ± s.e.m. [Two-Way ANOVA,
number of independent tests (n) = 3].
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